LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF7 | XMD11-85h | 0.37 | uM | LJP6 | 72 | hr | 1209 | 3735 | 4012 | 0.9340 | 0.9227 |
MCF7 | XMD11-85h | 1.11 | uM | LJP6 | 72 | hr | 1209 | 3420 | 4012 | 0.8521 | 0.8228 |
MCF7 | XMD11-85h | 3.33 | uM | LJP6 | 72 | hr | 1209 | 3452 | 4012 | 0.8600 | 0.8325 |
MCF7 | XMD11-85h | 10 | uM | LJP6 | 72 | hr | 1209 | 1830 | 4012 | 0.4564 | 0.2705 |
MCF7 | XMD16-144 | 0.04 | uM | LJP5 | 72 | hr | 1209 | 1543 | 4203 | 0.3684 | 0.1458 |
MCF7 | XMD16-144 | 0.12 | uM | LJP5 | 72 | hr | 1209 | 1550 | 4203 | 0.3694 | 0.1482 |
MCF7 | XMD16-144 | 0.37 | uM | LJP5 | 72 | hr | 1209 | 1495 | 4203 | 0.3560 | 0.1244 |
MCF7 | XMD16-144 | 1.11 | uM | LJP5 | 72 | hr | 1209 | 1515 | 4203 | 0.3611 | 0.1337 |
MCF7 | XMD16-144 | 3.33 | uM | LJP5 | 72 | hr | 1209 | 1457 | 4203 | 0.3477 | 0.1100 |
MCF7 | XMD16-144 | 10 | uM | LJP5 | 72 | hr | 1209 | 685 | 4203 | 0.1634 | -0.2713 |
MCF7 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 3874 | 4203 | 0.9233 | 0.9139 |
MCF7 | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 1209 | 3863 | 4203 | 0.9189 | 0.9076 |
MCF7 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1209 | 4208 | 4203 | 1.0017 | 1.0023 |
MCF7 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 1209 | 4308 | 4203 | 1.0255 | 1.0285 |
MCF7 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1209 | 4251 | 4203 | 1.0131 | 1.0156 |
MCF7 | Erlotinib | 10 | uM | LJP5 | 72 | hr | 1209 | 3651 | 4203 | 0.8706 | 0.8516 |
MCF7 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1209 | 4112 | 4012 | 1.0253 | 1.0295 |
MCF7 | Gefitinib | 0.12 | uM | LJP6 | 72 | hr | 1209 | 3983 | 4012 | 0.9927 | 0.9912 |
MCF7 | Gefitinib | 0.37 | uM | LJP6 | 72 | hr | 1209 | 3898 | 4012 | 0.9712 | 0.9657 |
MCF7 | Gefitinib | 1.11 | uM | LJP6 | 72 | hr | 1209 | 4054 | 4012 | 1.0093 | 1.0094 |
MCF7 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 1209 | 3922 | 4012 | 0.9767 | 0.9717 |
MCF7 | Gefitinib | 10 | uM | LJP6 | 72 | hr | 1209 | 3232 | 4012 | 0.8057 | 0.7652 |
MCF7 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4224 | 4203 | 1.0061 | 1.0075 |
MCF7 | Nilotinib | 0.12 | uM | LJP5 | 72 | hr | 1209 | 4205 | 4203 | 0.9983 | 0.9950 |
MCF7 | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 1209 | 4013 | 4203 | 0.9567 | 0.9522 |